Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity

• Published in: British journal of cancer 2009-05, Vol.100 (9), p.1393-1399
• Main Authors: Coleman, L J, Peter, M B, Teall, T J, Brannan, R A, Hanby, A M, Honarpisheh, H, Shaaban, A M, Smith, L, Speirs, V, Verghese, E T, McElwaine, J N, Hughes, T A
• Format: Article
• Language: English
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Biomarkers; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer Research; Clinical Study; Cohort Studies; Drug Resistance; Epidemiology; Eukaryotic Initiation Factor-4E - genetics; Eukaryotic Initiation Factor-4E - metabolism; Eukaryotic Initiation Factors - genetics; Eukaryotic Initiation Factors - metabolism; Female; Gene Expression Regulation, Neoplastic; Humans; Hypotheses; Immunohistochemistry; Influence; Medical prognosis; Medical research; Metastasis; Molecular Medicine; Oncology; Phosphoproteins - genetics; Phosphorylation; Prognosis; Protein expression; Protein synthesis; Proteins; Retrospective Studies; Survival Analysis
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/sj.bjc.6605044

Increased eukaryotic translation initiation factor 4E (eIF4E) expression occurs in many cancers, and makes fundamental contributions to carcinogenesis by stimulating the expression of cancer-related genes at post-transcriptional levels. This key role is highlighted by the facts that eIF4E levels can predict prognosis, and that eIF4E is an established therapeutic target. However, eIF4E activity is a complex function of expression levels and phosphorylation statuses of eIF4E and eIF4E-binding proteins (4E-BPs). Our hypothesis was that the combined analyses of these pathway components would allow insights into eIF4E activity and its influence on cancer. We have determined expression levels of eIF4E, 4E-BP1, 4E-BP2 and phosphorylated 4E-BP1 within 424 breast tumours, and have carried out analyses to combine these and relate the product to patient survival, in order to estimate eIF4E activity. We show that this analysis gives greater prognostic insights than that of eIF4E alone. We show that eIF4E and 4E-BP expression are positively associated, and that 4E-BP2 has a stronger influence on cancer behaviour than 4E-BP1. Finally, we examine eIF4E, estimated eIF4E activity, and phosphorylated 4E-BP1 as potential predictive biomarkers for eIF4E-targeted therapies, and show that each determines selection of different patient groups. We conclude that eIF4E's influence on cancer survival is modulated substantially by 4E-BPs, and that combined pathway analyses can estimate functional eIF4E.